You are here

Generic Equivalent of Zovirax Suspension Garners Approval

AMITYVILLE, N.Y.--(BUSINESS WIRE)--June 9, 2005--Hi-Tech Pharmacal Co., Inc. announced that the US Food and Drug Administration (FDA) has granted an approval to the Company's Abbreviated New Drug Application (ANDA) for Acyclovir Oral Suspension, USP 200 mg/5mL.

Hi-Tech's Acyclovir Oral Suspension, USP 200 mg/5mL is the generic equivalent of GlaxoSmithKline's Zovirax Suspension indicated for the treatment of herpes zoster infections, genital herpes and chicken pox. The Company expects to start marketing its Acyclovir Oral Suspension, USP 200 mg/5 mL in June, 2005.

Source: Hi-Tech Pharmacal Co.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs